The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis | Zendy

Ashraf S. Ibrahim | Zendy; Teclegiorgis Gebremariam | Zendy; Samuel W. French | Zendy; John E. Edwards | Zendy; Brad Spellberg | Zendy

Open Access

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis

Author(s) -

Ashraf S. Ibrahim,

Teclegiorgis Gebremariam,

Samuel W. French,

John E. Edwards,

Brad Spellberg

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp426

Subject(s) - deferasirox , aspergillus fumigatus , medicine , amphotericin b , combination therapy , pharmacology , myelodysplastic syndromes , aspergillosis , immunology , antifungal , bone marrow , thalassemia , dermatology

Increased bone marrow iron levels in patients with haematological malignancies is an independent risk factor for developing invasive pulmonary aspergillosis (IPA), suggesting an important role for iron uptake in the pathogenesis of IPA. We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research